COMMUNIQUÉS West-GlobeNewswire

GUERBET : Change in Guerbet’s Board of Directors.
11/03/2026
Change in Guerbet’s Board of Directors Villepinte, March 11th, 2026: Guerbet (FR0000032526 GBT), a global leader in contrast agents and solutions for medical imaging, today announced, at its Board of Directors’ meeting [...]
Human Appeal's #ForMama26 Campaign to Save only Maternity Hospital in Northwest Syria
11/03/2026
Partnership with Every Pregnancy aims to provide a critical lifeline for thousands of mothers and babies at Al Imaan Hospital through a matched funding campaign MISSION VIEJO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- [...]
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
11/03/2026
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups - Early [...]
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
11/03/2026
- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration [...]
GUERBET : Résultats annuels 2025.
11/03/2026
Résultats annuels 2025 Chiffre d’affaires : 786,4 M€, soit un repli de 3,5% à TCC 1 et périmètre comparable 2 , dû essentiellement à la baisse de l’activité en France Rentabilité : la marge d’EBITDA retraité 3 ressort à [...]
GUERBET : 2025 full-year results.
11/03/2026
2025 full-year results Revenue : €786.4 million, down 3.5% at CER 1 and like-for-like 2 , mainly due to the fall in activity in France Profitability : restated EBITDA margin 3 of 12.0% (at the high end of the adjusted [...]
GUERBET : Evolution du Conseil d’Administration de Guerbet.
11/03/2026
Evolution du Conseil d’Administration de Guerbet Villepinte, le 11 mars 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce la nomination ce [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
11/03/2026
Please see enclosed pdf. Attachment 11032026_trading_in_shares_JNA
Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000
11/03/2026
CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the purchase of $600,000 of [...]
Financière de Tubize - Investor call - 23/03/2026 - 17:00 CET
11/03/2026
Chers investisseurs, Nous organisons une réunion en ligne afin de présenter nos résultats annuels le 23 mars 2026 à 17h00 CET. Si vous souhaitez nous rejoindre, veuillez vous inscrire en cliquant sur le lien suivant : [...]
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
11/03/2026
Patients adherent to SUBLOCADE ® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD Patients adherent to SUBLOCADE had the lowest inpatient, emergency department, and [...]
Financière de Tubize - Investor call - 23/03/2026 - 17:00 CET
11/03/2026
Dear Investors, We will host an online investor call to present our annual results on March 23, 2026 at 17:00 CET. If you would like to join us, please register by clicking on or copying following link https://forms. [...]
Weight Watchers Report Finds Integrated GLP-1 Support Drives Significantly Greater Weight Loss Than Medication Alone
11/03/2026
Weight Watchers’ Med+ members who regularly engaged with their GLP-1 Success Program lost up to 61% more body weight in the first month and 29% more in one year, on average, than those who took medication alone. Med+ [...]
Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program
11/03/2026
- Company accelerating partner engagement ahead of pivotal clinical trial to be initiated in 2026 DUBLIN and WILSONVILLE, Ore., March 11, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage [...]
KOMO Biosciences Grants Research Evaluation License to Syngenta to Explore Precision Genome Modification in Maize
11/03/2026
Collaboration brings non-viral, site-specific DNA insertion to crop trait development, intended to accelerate the path to more resilient and sustainable agriculture CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- [...]
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
11/03/2026
“The strongest companies are built on the right foundations long before their moment arrives,” says CEO Jody Aufrichtig NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed [...]
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
11/03/2026
Vancouver, Canada, March 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
PolTREG poursuit la procédure d’enregistrement au niveau européen de sa thérapie à base de TREG destinée au traitement du diabète de type 1
11/03/2026
L’Agence européenne des médicaments (EMA) a officiellement autorisé PolTREG à déposer une demande d’autorisation de mise sur le marché dans l’Union européenne pour la préparation cellulaire PolTREG-T1D. GDAŃSK, Pologne [...]
24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making
11/03/2026
DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- 247marketnews.com -- In technology and biotechnology, “unicorn” status is typically reserved for private companies valued at $1 billion or more; often backed by major venture [...]

Pages